Email Alert RSS
Volume 12 Issue 6
Nov.  2021
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2021  >  12(6): 958-964
SUN Wenjuan, TANG Yan, ZOU Yuzhen, ZHANG Qian, ZHANG Bo, DU Xiaoli. Investigation on the Clinical Use of 17 Antineoplastic Drugs Passing National Medical Insurance Negotiation in Peking Union Medical College Hospital[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 958-964. doi: 10.3969/j.issn.1674-9081.2020.00.018
Citation: SUN Wenjuan, TANG Yan, ZOU Yuzhen, ZHANG Qian, ZHANG Bo, DU Xiaoli. Investigation on the Clinical Use of 17 Antineoplastic Drugs Passing National Medical Insurance Negotiation in Peking Union Medical College Hospital[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 958-964. doi: 10.3969/j.issn.1674-9081.2020.00.018
shu

Investigation on the Clinical Use of 17 Antineoplastic Drugs Passing National Medical Insurance Negotiation in Peking Union Medical College Hospital

doi: 10.3969/j.issn.1674-9081.2020.00.018

  • Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds:

Clinical Pharmacy Research Project of Beijing Pharmaceutical Associatio 2019

More Information
  • Corresponding author: DU Xiaoli  Tel: 86-10-69156515, E-mail: duxiaolipumch@163.com
  • Received Date: 2020-06-19
  • Accepted Date: 2020-10-13
    • Available Online: 2020-12-08
  • Publish Date: 2021-11-30
    Abstract
  •   Objective  The aim of this study is to investigate the clinical use of 17 antineoplastic drugs passing national medical insurance negotiation in Peking Union Medical College Hospital before and after the implementation of national policies about promoting the inclusion of antineoplastic drugs in health insurance, and to provide reference for the optimization and adjustment of hospital formulary.  Methods  The prescription data of 17 antineoplastic drugs of outpatients and inpatients in our hospital from December 1, 2017 to November 30, 2019(December 1, 2017 to November 30, 2018 for the year 2018, December 1, 2018 to November 30, 2019 for the year 2019) were collected. The basic information of patients, the usage amount and cost, defined daily doses (DDDs), and defined daily cost (DDC) were analyzed.  Results  A total of 6881 patients used the 17 antineoplastic drugs in 2019. Among them, there were 4713(68.5%) outpatients and 2168(31.5%) inpatients. The proportions of the cost of 17 antineoplastic drugs to that of all antineoplastic drugs and all formulary drugs in our hospital were 16.3% and 3.8%, respectively. The 17 antineoplastic drugs were mainly used for thorax, hematologic, and urologic malignancies. The top three antineoplastic drugs in terms of cost were osimertinib, octreotide acetate microspheres and crizotinib, with good synchronization between drug cost and DDDs. The top three drugs in terms of DDC were vemurafenib, cetuximab and ibrutinib. The total cost and prescription of the six drugs that had already been included in the formulary of our hospital before the implementation of the policy increased by 78.2% and 89.8%, respectively in 2019 compared with those in 2018, and the proportions of the cost of six antineoplastic drugs to that of all antineoplastic drugs and all formulary drugs in the hospital increased by 54.4% and 78.6%, respectively. After the implementation of national policies, the quantity and cost of osimertinib increased significantly, and the drugs increased in quantity but decreased in cost were cetuximab, axitinib, and sunitinib in sequence. Both the quantity and the cost of pegaspargase decreased significantly.  Conclusions  The national health insurance negotiation policy promoted the use of 17 antineoplastic drugs in the hospital and improved the accessibility of these drugs to patients significantly. At the same time, the total cost of the involved drugs had a sharp rise. It is necessary to strengthen the monitoring and dynamic evaluation of the clinical application of related drugs, so as to promote rational drug use while meeting patients' needs.
    • FullText(HTML)
  • loading
    • References(27)
  • [1] 国家医疗保障局. 国家医疗保障局办公室、人力资源社会保障部办公厅、国家卫生健康委办公厅. 关于做好17种国家医保谈判抗癌药执行落实工作的通知[EB/OL]. (2018-11-29)[2020-02-22]. http://www.nhsa.gov.cn/art/2018/11/29/art_37_403.html.
    [2] 北京市人力资源和社会保障局. 关于将国家谈判的17种抗癌药纳入本市基本医疗保险工伤保险和生育保险药品报销范围的通知[EB/OL]. (2018-11-29)[2020-02-22]. http://rsj.beijing.gov.cn/xxgk/zcwj/201912/t2019 1206_943339.html.
    [3] American Jonit Committee on Cancer. Cancer Staging Manual Eighth Edition[M]. Springer Nature, 2016.
    [4] 世界卫生组织药物统计方法合作中心. ATC/DDD索引[EB/OL]. (2020-12-17)[2021-02-28]. https://www.whocc.no/atc_ddd_index/.
    [5] 国家药典委员会. 中华人民共和国药典2015年版: 一部[S]. 北京: 中国医药科技出版社, 2015.
    [6] 陈新谦, 金有豫, 汤光. 新编药物学第18版[S]. 北京: 人民卫生出版社, 2018.
    [7] Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC[J]. N Engl J Med, 2020, 382: 41-50. doi:  10.1056/NEJMoa1913662
    [8] Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. N Engl J Med, 2018, 378: 113-125. doi:  10.1056/NEJMoa1713137
    [9] Ricciuti B, Baglivo S, De Giglio A, et al. Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience[J]. Ther Adv Respir Dis, 2018, 1: 1-13. doi:  10.15342/ATD.V1IR.249
    [10] 中国抗癌协会肺癌专业委员会. EGFR-TKI不良反应管理专家共识[J]. 中国肺癌杂志, 2019, 22: 57-81.
    [11] Batson S, Mitchell SA, Windisch R, et al. Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis[J]. Onco Targets Ther, 2017, 5: 2473-2482. http://www.dovepress.com/getfile.php?fileID=36355
    [12] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Non-Small Cell Lung Cancer[EB/OL]. (2020-01-18)[2020-03-01]. https://www.nccn.org/professionals/default.aspx.
    [13] 孙雯娟, 张波. 间变性淋巴瘤激酶抑制剂作用机制与耐药机制研究进展[J]. 临床药物治疗杂志, 2019, 17: 10-14.
    [14] 中国医师协会血液科医师分会, 中华医学会血液学分会, 中国医师协会多发性骨髓瘤专业委员会. 《中国多发性骨髓瘤诊治指南(2017年修订)》[J]. 中华内科杂志, 2017, 56: 866-870. doi:  10.3760/cma.j.issn.0578-1426.2017.11.021
    [15] Kumar SK, Laplant BR, Reeder CB, et al. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib[J]. Blood, 2016, 128: 2415-2422. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5114487/?report=printable
    [16] Cai H, Zhang L, Li N, et al. Cost-effectiveness analysis on binary/triple therapy on the basis of ixazomib or bortezomib for refractory or relapsed multiple myeloma[J]. Leuk Lymphoma, 2019, 60: 2951-2959. doi:  10.1080/10428194.2019.1620947
    [17] 中华人民共和国国家健康委员会. 成人慢性粒细胞白血病诊疗规范(2018年版)[EB/OL]. (2018-12-21)[2020-04-21]. http://www.nhc.gov.cn/yzygj/s7659/201812/b21802b199814ab7b1219b87de0cae51.shtml.
    [18] 李艳玲, 王振磊, 张梅, 等. 靶向酪氨酸激酶小分子抑制剂伊布替尼的临床研究进展[J]. 中国新药杂志, 2019, 28: 2232-2239. doi:  10.3969/j.issn.1003-3734.2019.18.011
    [19] 杨阿丽, 刘欣, 王兴兵, 等. 第一代与第二代TKI治疗慢性粒细胞白血病的疗效[J]. 医学信息, 2019, 32: 78-81.
    [20] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Chronic Myeloid Leukemia[EB/OL]. (2020-01-18)[2020-03-01]. https://guide.medlive.cn/guideline/17986.
    [21] Hiwase D, Tan P, D'Rozario J, et al. Efficacy and safety of nilotinib 300mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase Ⅲb ENESTswift study[J]. Leuk Res, 2018, 67: 109-115. doi:  10.1016/j.leukres.2018.02.013
    [22] 国家卫生健康委员会. 胃癌诊疗规范(2018年版)[J]. 中华消化病与影像杂志(电子版), 2019, 9: 118-144.
    [23] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Kidney Cancer[EB/OL]. (2019-04-25)[2020-03-01]. https://www.nccn.org/professionals/default.aspx.
    [24] 潘秀武, 曲发军, 张向民, 等. 培唑帕尼新辅助治疗在减瘤性肾切除术治疗转移性肾癌患者中的安全性和有效性分析[J]. 临床泌尿外科杂志, 2019, 34: 933-936.
    [25] Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma[J]. N Engl J Med, 2013, 369: 722-731. http://media.wix.com/ugd/17dcca_4472ee3055d14e2e88cafeb9c44dcaa1.pdf
    [26] 王艳, 吴晓玲, 门鹏, 等. 培唑帕尼治疗晚期/转移性肾细胞癌的有效性、安全性和经济性的快速卫生技术评估[J]. 中国新药杂志, 2019, 28: 3030-3034.
    [27] 刘海娇, 吴玉霞, 徐伟. 转移性肾癌一线治疗药物舒尼替尼、索拉非尼和培唑帕尼的药物经济学评价文献研究[J]. 中国药房, 2020, 31: 612-616.
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (430) PDF downloads(80) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return